OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Randolph on Future Treatment Approaches in Thyroid Cancer

October 11th 2016

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses the future methods of treating patients with thyroid cancer.

Dr. Wistuba on Maximizing Outcomes With Limited Tissue in Lung Cancer

October 11th 2016

Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, Anderson Clinical Faculty Chair for Cancer Treatment and Research, The University of Texas MD Anderson Cancer Center, discusses how pathologists maximize outcomes with limited tissue in patients with lung cancer.

Dr. Jerald P. Radich on Treatment Considerations with Generic Imatinib in CML

October 8th 2016

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses which patients should receive the newly approval generic imatinib versus second-generation tyrosine-kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).

Dr. Ruben Mesa on Impact of New NCCN Guidelines for MPN

October 8th 2016

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the significance of the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).

Dr. Heinemann on Implications of SIRFLOX Study for mCRC

October 7th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the broad clinical implications of the SIRFLOX findings for patients with metastatic colorectal cancer (mCRC).

Dr. Burris on Remaining Challenges in Treating HER2+ Breast Cancer

October 7th 2016

Howard A. “Skip” Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, a 2014 Giant of Cancer Care in Drug Development, discusses the biggest remaining challenges in treating patients with HER2-positive breast cancer.

Dr. Kiran Turaga on Regional Therapies in Melanoma

October 7th 2016

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discuses regional therapies in melanoma.

Dr. Kaufman on T-VEC in Melanoma

October 7th 2016

Howard L. Kaufman, MD, chief surgical officer, associate director for Clinical Science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses oncolytic immunotherapy talimogene laherparepvec (T-VEC; Imlygic) for treatment of patients with melanoma, as well as the agent's side effect profile.

Dr. Zhang on Therapeutic Advancements in Prostate Cancer

October 7th 2016

Jingsong Zhang, MD, PhD, discusses the advancements for patients with metastatic castration-resistant prostate cancer (mCRPC) that have occurred over the last decade.

Stefani Spranger on Immunotherapy Versus Chemotherapy

October 7th 2016

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses the differences between immunotherapy and chemotherapy.

Erin Kopp on the Toxicities of Cutaneous T-cell Lymphoma Treatment

October 6th 2016

Erin Kopp, ACNP-BC, City of Hope Comprehensive Cancer Center, on managing the side effects of cutaneous T-cell lymphoma treatment.

Dr. Richard M. Stone on the Genetic Landscape in AML

October 6th 2016

Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).

Dr. Hamilton on Research Needed in HER2-Positive Breast Cancer

October 6th 2016

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses necessary research oncologists should begin conducting in the space of HER2-positive breast cancer.

Dr. Dorff on Role of Chemotherapy in mCRPC

October 6th 2016

Tanya Dorff, MD, assistant professor of Clinical Medicine, Keck Medicine of University of Southern California, discusses the role of chemotherapy in patients with metastatic castration-resistant prostate cancer and pivotal clinical trials that have explored this.

Dr. Horwitz on Combination CHOP Regimens in Peripheral T-cell Lymphoma

October 5th 2016

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering, discusses the evolving role of CHOP in peripheral T-cell lymphoma. For years CHOP or a similar regimen has been the standard treatment for peripheral T-cell lymphoma.

Dr. Jonas de Souza on the Impact of Pembrolizumab Approval in Head and Neck Cancer

October 5th 2016

Jonas de Souza, MD, assistant professor of medicine, University of Chicago, discusses the approval of pembrolizumab for relapsed head and neck cancer patients who are platinum-refractory

Dr. Micallef on NuQ Blood Tests in Prostate Cancer

October 5th 2016

Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses the science of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.

Dr. Bergstrom on XMT-1536 in Ovarian Cancer

October 5th 2016

Donald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1536.

Dr. Weber on Selecting Immunotherapy for Patients With Melanoma

October 5th 2016

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses considering factors when selecting an immunotherapy agent for a patient with melanoma.

Dr. Stephans on Treatment for Oligometastatic Lung Cancer

October 5th 2016

Kevin Stephans, MD, associate staff, Radiation Oncology at Cleveland Clinic, discusses advancements in the treatment of patients with oligometastatic lung cancer.